Oligomerix to Present at Biotech Showcase™ 2014

News provided by

Jan 07, 2014, 10:17 ET

NEW YORK, Jan. 7, 2014 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today that James Moe, PhD, President & CEO, will be presenting at the Biotech Showcase™ 2014 Conference.

Details of Oligomerix's presentation are as follows:

Event:		Biotech Showcase™ 2014 Conference
Date:		January 14, 2104
Time:		9:15 a.m. PT
Location:		Room B - Mission I (4th Floor): Parc 55 Wyndham San Francisco, CA

ABOUT OLIGOMERIX
Oligomerix, Inc. is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The Company was founded in 2006 and is headquartered at Audubon Biomedical Science and Technology Park at Columbia University Medical Center and is carrying out its in vivo studies at New York Medical College. The Company is seeking strategic partners to help accelerate these exciting programs. For more information, visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition and dependence on government agencies and other third parties for funding contract research and services.

CONTACTS:

Oligomerix,

Jack Pasini

Chief Commercial Officer

Oligomerix, Inc

917-912-4088

[email protected]

Tiberend Strategic Advisors, Inc.

Andrew Mielach

212-375-2694

[email protected]

SOURCE Oligomerix, Inc.